Blockchain Registration Transaction Record

Lexaria Bioscience Releases Positive Interim Results from WEIGHT-A24-1 Animal Study

Lexaria Bioscience (NASDAQ: LEXX) releases positive interim results from WEIGHT-A24-1 animal study, demonstrating the potential of its DehydraTECH technology for diabetes and weight loss treatments.

Lexaria Bioscience Releases Positive Interim Results from WEIGHT-A24-1 Animal Study

This news matters because it demonstrates the potential of Lexaria's DehydraTECH technology to address diabetes and weight loss, which could have a significant impact on the global market for these treatments. Investors and individuals interested in innovative drug delivery platforms and advancements in diabetes management should take note of these positive findings.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x1597d83105a28fd7ff4c3dbe6476b985246e7d2a962d73c52f52263d661b8e5a
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintapexbGpN-25dafaaa1157a5e634c3aeff036303a5